Department of Psychiatry, University of Maryland Medical Center, Baltimore, MD, USA.
Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health System, 6501 N. Charles Street, Towson, MD, USA.
Curr Psychiatry Rep. 2022 Oct;24(10):583-590. doi: 10.1007/s11920-022-01363-y. Epub 2022 Sep 21.
Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin.
Several studies have coupled the safe administration of psychedelic compounds in a controlled environment after several hours of preparation of study participants and followed by multiple sessions to integrate the psychedelic experience. The improvement participants experience appear related to the often profound perspective changes experienced and seem unlike the improvements seen in the currently available care paradigms. Studies cited include treatment resistant depression, end of life despair, and PTSD. Psychedelic psychotherapy, a unique remarriage of biological therapy and psychotherapy, has the potential to transform mental health care.
对于已经多次尝试过多种干预措施但仍未改善的情绪障碍或创伤后应激障碍（PTSD）患者，目前治疗方法有限。在经过几十年的联邦立法有效阻止迷幻剂研究之后，过去几年显示出重新进行深思熟虑的研究，以评估 3,4-亚甲二氧基甲基苯丙胺（MDMA）和裸盖菇素等化合物的用途。
多项研究在对研究参与者进行数小时的准备后，在受控环境中安全地管理迷幻化合物，然后进行多次治疗，以整合迷幻体验。参与者所经历的改善似乎与他们所经历的深刻观点变化有关，与目前可用的治疗模式所看到的改善不同。引用的研究包括治疗抵抗性抑郁症、临终绝望和 PTSD。迷幻心理疗法，是生物治疗和心理治疗的独特再结合，有可能改变精神保健。
